• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    11/6/24 5:08:24 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTX alert in real time by email
    SC 13G/A 1 cntx_13ga.htm CNTX 13G/A

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Context Therapeutics Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    21077P108

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Hudson Bay Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,000,000 shares of Common Stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,000,000 shares of Common Stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,000,000 shares of Common Stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.32%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Sander Gerber

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,000,000 shares of Common Stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,000,000 shares of Common Stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,000,000 shares of Common Stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.32%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     
     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Context Therapeutics Inc., a Delaware corporation (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by Hudson Bay Capital Management LP (the "Investment Manager") and Mr. Sander Gerber ("Mr. Gerber"), who are collectively referred to herein as "Reporting Persons."

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 28 Havemeyer Place, 2nd Floor, Greenwich, Connecticut 06830.

     

    Item 2(c). CITIZENSHIP:
       
      The Investment Manager is a Delaware limited partnership.  Mr. Gerber is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      21077P108

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ý Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

     
     

     

      (g) ý

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentages used in this Schedule 13G are calculated based upon 74,998,312 shares of Common Stock outstanding as of August 6, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission on August 7, 2024 and assumes the exercise of the warrants held by Hudson Bay Master Fund Ltd.  
       
      The Investment Manager serves as the investment manager to Hudson Bay Master Fund Ltd., in whose name the securities reported herein are held. As such, the Investment Manager may be deemed to be the beneficial owner of all shares of Common underlying the warrants held by Hudson Bay Master Fund Ltd. Mr. Gerber serves as the managing member of Hudson Bay Capital GP LLC, which is the general partner of the Investment Manager.  Mr. Gerber disclaims beneficial ownership of these securities.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 4.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
     
     

     

       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 6, 2024

     

    HUDSON BAY CAPITAL MANAGEMENT LP    
         
         
    By: /s/ Sander Gerber    
    Name: Sander Gerber    
    Title: Authorized Signatory    
         
         
    /s/ Sander Gerber    
    SANDER GERBER    

     

    Get the next $CNTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNTX

    DatePrice TargetRatingAnalyst
    4/21/2025Outperform
    William Blair
    1/8/2025$4.00Mkt Outperform
    JMP Securities
    11/25/2024$9.00Buy
    D. Boral Capital
    5/16/2024$4.50Overweight
    Piper Sandler
    2/2/2022$6.00Buy
    HC Wainwright & Co.
    1/24/2022$10.00Buy
    ThinkEquity
    More analyst ratings

    $CNTX
    Financials

    Live finance-specific insights

    See more
    • Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

      CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We continue to advance our clinical pipeline and are pleased to have two product c

      5/7/25 4:09:57 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Context Therapeutics Reports Full Year 2024 Operating and Financial Results

      CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We believe 2024 was a transformative year for Context, marked by strategic acquisitions, a s

      3/20/25 4:22:37 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

      Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board with appointments of Dr. Karen Smith and Dr. Luke Walker Cash and cash equivalents of $84.8 million as of September 30, 2024 PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced its financial results for the third quarter ended September 30, 2024, and reported on recent and upcoming business highlights. "Context executed on its strategy to bui

      11/6/24 4:06:13 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

      Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who stepped down from the Board effective January 12, 2025.  "I am honored to become the next Chairman of the Board of Directors of Context, where I expect to leverage my experience advising and building fully int

      1/13/25 7:30:07 AM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

      PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. "Karen and Luke's vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Context at this pivotal stage of our growth," said Martin Lehr, CEO of Context Therapeutics. "Karen's extensive oncology drug development, regulatory, and strategy experience will be invaluable as Context continues to advance its pipeline. Luke brings an extensive track record in

      9/4/24 7:30:47 AM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

      Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company's two clinical-stage T cell engaging assets to treat solid tumors PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer ("CMO") and Karen Andreas, M.S. as Vice President, Clinical Operations. "We are thrilled to welcome Dr. Dansky Ullmann and Ms. Andreas to our team at this exciting time as the Company adv

      8/1/24 7:30:00 AM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Context Therapeutics

      William Blair initiated coverage of Context Therapeutics with a rating of Outperform

      4/21/25 8:38:14 AM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Context Therapeutics with a new price target

      JMP Securities initiated coverage of Context Therapeutics with a rating of Mkt Outperform and set a new price target of $4.00

      1/8/25 7:37:35 AM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • D. Boral Capital initiated coverage on Context Therapeutics with a new price target

      D. Boral Capital initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $9.00

      11/25/24 8:20:51 AM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

      SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

      11/14/24 5:31:29 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Context Therapeutics Inc.

      SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

      11/14/24 5:05:15 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

      SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

      11/14/24 4:52:28 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

      CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We continue to advance our clinical pipeline and are pleased to have two product c

      5/7/25 4:09:57 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Context Therapeutics Announces Chief Medical Officer Transition

      PHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced Dr. Karen Smith, MD, PhD, MBA, LLM as interim Chief Medical Officer ("CMO"). Dr. Smith replaces Dr. Claudio Dansky Ullmann, who will be leaving the Company effective May 10, 2025. Dr. Smith will continue in a dual capacity as interim CMO and a member of the Company's Board of Directors ("Board") while the Company conducts a search for a new, full-time CMO. Dr. Smith will take over key responsibilities on an interim basis, ensuring continuity in strategic g

      5/5/25 4:05:50 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

      Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin  Data supports ongoing Phase 1 clinical trial for CT-95   PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced preclinical and translational data regarding the Company's clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL.  "There is a high unmet ne

      4/30/25 7:30:46 AM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Context Therapeutics Inc.

      SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

      5/9/25 1:08:10 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Context Therapeutics Inc.

      10-Q - Context Therapeutics Inc. (0001842952) (Filer)

      5/7/25 4:05:50 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Context Therapeutics Inc.

      DEFA14A - Context Therapeutics Inc. (0001842952) (Filer)

      4/15/25 4:06:09 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Minai-Azary Jennifer Lynn

      4 - Context Therapeutics Inc. (0001842952) (Issuer)

      2/14/25 4:13:21 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer, Corp. Sec Levit Alex C.

      4 - Context Therapeutics Inc. (0001842952) (Issuer)

      2/14/25 4:11:55 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Dansky Ullmann Claudio

      4 - Context Therapeutics Inc. (0001842952) (Issuer)

      2/14/25 4:07:37 PM ET
      $CNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care